SEC Filings
Artivion Revenue Grows 9% On Reported And Currency-Neutral Bases — Adjusted Profit Falls
The cardiac-surgery company narrowed its full-year outlook as it prepares to launch NEXUS in the U.S. in January 2027.
Artivion (AORT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The cardiac-surgery company narrowed its full-year outlook as it prepares to launch NEXUS in the U.S. in January 2027.
Earnings
CEO Pat Mackin calls the purchase-order bottleneck administrative and transient, and the company narrowed 2026 growth guidance to 8% to 10%.